|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CYRIB |
Gene summary for CYRIB |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CYRIB | Gene ID | 51571 |
| Gene name | CYFIP related Rac1 interactor B | |
| Gene Alias | BM-009 | |
| Cytomap | 8q24.21 | |
| Gene Type | protein-coding | GO ID | GO:0000266 | UniProtAcc | A0A024R9G4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51571 | CYRIB | CA_HPV_1 | Human | Cervix | CC | 2.84e-03 | 1.84e-01 | 0.0264 |
| 51571 | CYRIB | N_HPV_2 | Human | Cervix | N_HPV | 3.16e-03 | 1.85e-01 | -0.0131 |
| 51571 | CYRIB | CCI_1 | Human | Cervix | CC | 1.93e-06 | -5.20e-01 | 0.528 |
| 51571 | CYRIB | CCI_2 | Human | Cervix | CC | 8.18e-06 | -5.20e-01 | 0.5249 |
| 51571 | CYRIB | CCI_3 | Human | Cervix | CC | 5.72e-09 | -5.20e-01 | 0.516 |
| 51571 | CYRIB | CCII_1 | Human | Cervix | CC | 7.66e-13 | -5.20e-01 | 0.3249 |
| 51571 | CYRIB | Tumor | Human | Cervix | CC | 6.17e-26 | -5.20e-01 | 0.1241 |
| 51571 | CYRIB | sample1 | Human | Cervix | CC | 1.45e-10 | -5.20e-01 | 0.0959 |
| 51571 | CYRIB | sample3 | Human | Cervix | CC | 2.98e-28 | -5.20e-01 | 0.1387 |
| 51571 | CYRIB | H2 | Human | Cervix | HSIL_HPV | 2.98e-28 | -5.20e-01 | 0.0632 |
| 51571 | CYRIB | L1 | Human | Cervix | CC | 3.46e-14 | -5.20e-01 | 0.0802 |
| 51571 | CYRIB | T1 | Human | Cervix | CC | 5.04e-24 | -5.20e-01 | 0.0918 |
| 51571 | CYRIB | T2 | Human | Cervix | CC | 1.97e-05 | -5.20e-01 | 0.0709 |
| 51571 | CYRIB | T3 | Human | Cervix | CC | 4.34e-27 | -5.20e-01 | 0.1389 |
| 51571 | CYRIB | HTA11_3410_2000001011 | Human | Colorectum | AD | 8.85e-17 | 3.24e-01 | 0.0155 |
| 51571 | CYRIB | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.28e-26 | 6.02e-01 | -0.1808 |
| 51571 | CYRIB | HTA11_2951_2000001011 | Human | Colorectum | AD | 3.22e-05 | 3.08e-01 | 0.0216 |
| 51571 | CYRIB | HTA11_1938_2000001011 | Human | Colorectum | AD | 7.66e-36 | 8.32e-01 | -0.0811 |
| 51571 | CYRIB | HTA11_78_2000001011 | Human | Colorectum | AD | 2.21e-33 | 8.00e-01 | -0.1088 |
| 51571 | CYRIB | HTA11_347_2000001011 | Human | Colorectum | AD | 1.60e-53 | 8.72e-01 | -0.1954 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001082114 | Cervix | N_HPV | regulation of mitochondrion organization | 11/534 | 144/18723 | 2.83e-03 | 2.45e-02 | 11 |
| GO:003227124 | Cervix | N_HPV | regulation of protein polymerization | 15/534 | 233/18723 | 2.92e-03 | 2.51e-02 | 15 |
| GO:011005325 | Cervix | N_HPV | regulation of actin filament organization | 16/534 | 278/18723 | 6.37e-03 | 4.37e-02 | 16 |
| GO:005149413 | Cervix | N_HPV | negative regulation of cytoskeleton organization | 11/534 | 163/18723 | 7.17e-03 | 4.72e-02 | 11 |
| GO:0007015 | Colorectum | AD | actin filament organization | 167/3918 | 442/18723 | 1.65e-16 | 7.94e-14 | 167 |
| GO:0032535 | Colorectum | AD | regulation of cellular component size | 142/3918 | 383/18723 | 1.74e-13 | 3.41e-11 | 142 |
| GO:1902903 | Colorectum | AD | regulation of supramolecular fiber organization | 139/3918 | 383/18723 | 2.01e-12 | 3.19e-10 | 139 |
| GO:0032970 | Colorectum | AD | regulation of actin filament-based process | 142/3918 | 397/18723 | 4.05e-12 | 5.90e-10 | 142 |
| GO:0110053 | Colorectum | AD | regulation of actin filament organization | 108/3918 | 278/18723 | 5.02e-12 | 6.98e-10 | 108 |
| GO:0008154 | Colorectum | AD | actin polymerization or depolymerization | 90/3918 | 218/18723 | 6.14e-12 | 8.23e-10 | 90 |
| GO:0032271 | Colorectum | AD | regulation of protein polymerization | 94/3918 | 233/18723 | 1.01e-11 | 1.29e-09 | 94 |
| GO:0030041 | Colorectum | AD | actin filament polymerization | 81/3918 | 191/18723 | 1.35e-11 | 1.69e-09 | 81 |
| GO:0051258 | Colorectum | AD | protein polymerization | 112/3918 | 297/18723 | 1.85e-11 | 2.27e-09 | 112 |
| GO:0043254 | Colorectum | AD | regulation of protein-containing complex assembly | 148/3918 | 428/18723 | 2.64e-11 | 3.18e-09 | 148 |
| GO:0008064 | Colorectum | AD | regulation of actin polymerization or depolymerization | 79/3918 | 188/18723 | 4.17e-11 | 4.74e-09 | 79 |
| GO:0030833 | Colorectum | AD | regulation of actin filament polymerization | 74/3918 | 172/18723 | 4.50e-11 | 5.03e-09 | 74 |
| GO:0030832 | Colorectum | AD | regulation of actin filament length | 79/3918 | 189/18723 | 5.71e-11 | 6.27e-09 | 79 |
| GO:0032956 | Colorectum | AD | regulation of actin cytoskeleton organization | 127/3918 | 358/18723 | 1.03e-10 | 1.04e-08 | 127 |
| GO:0010639 | Colorectum | AD | negative regulation of organelle organization | 114/3918 | 348/18723 | 1.41e-07 | 6.49e-06 | 114 |
| GO:0010821 | Colorectum | AD | regulation of mitochondrion organization | 57/3918 | 144/18723 | 2.43e-07 | 9.92e-06 | 57 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |